DRUG EVALUATION IN THE PLASHODIUM FALCIPARUM-AOTUS MODEL(U) CORGAS MEMORIAL LAB APO MIAMI 34002 R N ROSSAN 30 SEP 86 DANDI?-84-C-4215 AD-A193 220 1/1 F/G 6/15 UNCLASSIFIED NL END



AD\_\_\_\_\_

# DRUG EVALUATION IN THE PLASMODIUM

FALCIPARUM-AOTUS MODEL (U)

ANNUAL REPORT

Richard N. Rossan

(For the period August 1, 1985 to July 31, 1986)

September 30, 1986

Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND Fort Detrick Frederick, Maryland 21701-5102

Contract No. DAMD17-84-C-4215

Gorgas Memorial Laboratory Panama, Republic of Panama

DOD DISTRIBUTION STATEMENT



Approved for public release; distribution unlimited.

The views, opinions, and/or findings contained in this report are those of the author and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

	_	Ŧ	7.5	_	_	_	-	-	_	_	-	_	_	-	_				_				_
. I	•	 Ю	11	. ~	•		•	٠,	e١	r	10		Ā		 	_	5	Ť	 	P	•	_	Ē

		REPORT (	OCUMENTATIO	N PAGE			Form Approved OMB No. 0704-0188		
9	ECURITY CLASS	SIFICATION		16. RESTRICTIVE	MARKINGS		A		
Unclassi		N AUTHORITY		2 DISTRIBUTION	AVAILABILITY OF	PERCET			
Za. SECURITY	CLASSIFICATIO	N AUTHORITY							
2b. DECLASSI	FICATION / DOV	VNGRADING SCHEDU	LE		for public r ion unlimite		· <b>;</b>		
4. PERFORMIN	IĞ ORGANIZAT	ION REPORT NUMBE	R(S)	5. MONITORING	ORGANIZATION RI	PORT NU	JMBER(S)		
		ORGANIZATION	6b. OFFICE SYMBOL (If applicable)	7a. NAME OF M	ONITORING ORGAI	NOITASIN			
Gorgas M	lemorial L	aboratory	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
6c. ADDRESS	(City, State, an	d ZIP Code)		76. ADDRESS (C	ty, State, and ZIP (	ode)			
Panama,	Republic	of Panama							
8a. NAME OF ORGANIZA	FUNDING/SPC	NSORING Army Medical	8b OFFICE SYMBOL (If applicable)	9. PROCUREMEN	T INSTRUMENT ID	NTIFICAT	TON NUMBER		
		pment Command	(	Contrac	t No. DAMD17	-84-C-	4215		
8c. ADDRESS (	City, State, and	ZIP Code)			FUNDING NUMBER				
Fort Det	rick			PROGRAM ELEMENT NO.	PROJECT NO 3M1-	TASK NO.	WORK UNIT ACCESSION NO.		
Frederic	k, Maryla	nd 21701-5012		62770A	62770A870	Λ	.T 028		
	ude Security Columbia	·	ium Falciparum -	- Aotus Mod	e1				
12. PERSONAL	N. Rossan	nt. n			<u> </u>				
13a. TYPE OF		13b. TIME CO	OVERED	14. DATE OF REPO	ORT (Year, Month,	Day) 15	. PAGE COUNT		
Annua1	Report	FROM <u>8/1</u>	L <u>/85</u> το <u>7/31/</u> 86	1986 Se	ptember 30		49		
16. SUPPLEME	NTARY NOTAT	TION							
17. COSATI CODES 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)  FIELD GROUP SUB-GROUP Plasmodium falciparum curative drugs									
FIELD GROUP SUB-GROUP Plasmodium falciparum curative drugs									
06 13 Aotus trivirgatus 9-phenanthrenemethanol 06 20 blood schizonticidal drugs 2-fluoro-l-histidine									
06 20 blood schizonticidal drugs 2-fluoro-l-histidine  19. ABSTRACT (Continue on reverse if necessary and identify by block number)									
tive) ( luate   1	or Vietnam the blood 547 and WF of 0.5 or doses rati 250548. neither used; WR 1 intravence upon Uga as a sing of 100.0 m	n Smith (chlo schizonticida R 250548, ster 1.0 mg base p ios were equal Three 9-phenan the chloride 122455 cured tous dose of 2- anda Palo Alto gle intravenou	er kg (x 3 days ly effective inchrenemethanols or biquinate sa hese treatment fluoro-1-histid strain parasites dose of 200.0, no antimalaria	nt), in Aotu activity of oxacrine, ad ) cleared an dicating a p were evalu lts of halof failures as ine of 50.0 emias. When or 400.0 mg al activity	experimental ministered in dor cured wo tentiating lated against antrine were well as primor 100.0 mg 2-iodo-hist base per kowas observed	anting anting anting anting anting anting effect ary ir base partials or as an anting and an anting	re used to eva- malarial drugs. pination each at m Smith infections t of WR 250547 mam Smith infec- ective, at the merky had no was administered,		
	F RESPONSIBLE		D DIIC OSEKS	22b TELEPHONE	(Include Area Code	) 22c O	FFICE SYMBOL		
	rginia M.			301/66			RD-RMI-S		

- 18. acridinol
  2-iodo-histidine
  3 sodim artesunate
- 19. administered intravenously at a dose of 30.0 mg per kg (x 2 days), temporarily suppressed Uganda Palo Alto parasitemia. Trials are in progress to adapt the UNC-W2-MEF clone of the CDC Indochina III strain of  $\underline{P}$ .  $\underline{falciparum}$  to  $\underline{Aotus}$ .

#### SUMMARY.

The primary goal of these studies was to evaluate experimental antimalarial drugs in a non-human primate model: blood-induced infections of <u>Plasmodium</u> falciparum in the Panamanian owl monkey <u>Aotus</u>. Two strains of falciparum malaria, Uganda Palo Alto (sensitive to chloroquine and quinine, resistant to pyrimethamine) and Vietnam Smith (resistant to chloroquine, quinine and pyrimethamine) were used.

Previous evaluation of two stereoisomers of floxacrine indicated that WR 250547 cured Vietnam Smith infections when administered at doses of 1.0, 4.0 or 16.0 mg base per kg (x 3 days). WR 250548, however, did not clear and/or cure Vietnam Smith infections when administered at similar doses. When both drugs were administered, in combination, against Vietnam Smith infections a potentiating effect was observed. WR 250547 and WR 250548, each administered at a dose of 0.5 or 1.0 mg base per kg (x 3 days) cleared and/or cured Vietnam Smith infections. Other dose ratios of 0.5 and 2.0, 2.0 and 0.5, 1.0 and 4.0, and 4.0 and 1.0, were equally effective in curing infections of the Vietnam Smith strain.


Three 9-phenathrenemethanols were evaluated against infections of the multidrug resistant Vietnam Smith strain. The chloride salt of halofantrine, WR 171 669AM, cured two infections out of a total of 22 treatments. Doses of 2.9, 5.8 or 11.7 mg base per kg (x 3 days) were not effective against primary parasitemias. The biquinate salt of halofantrine, WR 171699AP, did not clear primary parasitemias when administered at dose of 2.9, 5.8 or 11.7 mg base per kg (x 3 days) and after retreatments cured one of 21 infections. WR 122455 at a dose of 5.8 or 11.7 mg base per kg (x 3 days) cured 3 of 4 primary infections, and all recrudescences following treatment with either WR 171669AM or WR 171699AP.

A prior evaluation of 2-fluored-histidine (WR 251835) showed that a dose of 25.0 mg base per kg (x 7 days) suppressed parasitemia of the Uganda Palo Alto strain and a 50.0 mg base per kg dose was toxic by the sixth day of administration. A re-evaluation of 2-fluoro-l-histidine administered as a single intravenous dose of 50.0 or 100.0 mg base per kg had no effect upon Uganda Palo Alto parasitemias. The 2-iodo-histidine analogue was administered as a single intravenous dose of 200.0 or 400.0 mg base per kg. No activity against infections of the Uganda Palo Alto strain was observed. The monkeys were re-treated orally with three 100.0 mg base per kg doses, but this regimen had no effect upon the parasites.

A pilot evaluation of sodium artesunate, a derivative of Qinghaosu, showed that intravenous administration of a 30.0 mg per kg (x 2 days) dose suppressed temporarily Uganda Palo Alto parasitemia in one  $\underline{Aotus}$ .

Trials are in progress in adapting the UNC-W2-MEF clone of the CDC Indochina III strain of P. falciparum to Aotus. To date, parasitemias greater than 1,000 per mm<sup>3</sup> have been obtained only in a splenectomized Aotus of Colombian origin.





### FOREWORD

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).

# TABLE OF CONTENTS

	<u>Page</u>
DD FORM 1473	ii
SUMMARY	iv
FOREWORD	٧
TABLE OF CONTENTS	νi
EXPERIMENTAL PROCEDURES  Figure 1 - Schema for drug evaluation against Plasmodium falciparum trophozoite - induced infections in Aotus trivirgatus	1 2
ASSESSMENT OF THE ANTIMALARIAL ACTIVITY OF WR 250547AA (BN: BK 51630) AND WR 250548AA (BN: BK 51621), IN COMBINATION, AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM	3
Tables 1 - 3	5 - 7
ASSESSMENT OF THE ANTIMALARIAL ACTIVITIES OF THREE 9-PHENANTHRENEMETHANOLS AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM	8
A. WR 171669AM (BN: BK 64002)	9
B. WR 171669AP (BN: BL 08009)	10
C. WR 122455AF (BN: AX 26839)	11
Tables 4 - 12	13 -22
ASSESSMENT OF THE ANTIMALARIAL ACTIVITIES OF 2-FLUORO-L-HISTIDINE AND 2-IODO-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM	23
Tables 13 - 18	27 - 32
PILOT EVALUATION OF SODIUM ARTESUNATE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM	33
Tables 19 - 20	35 - 36

	Page
ADAPTATION TRIALS IN <u>AOTUS</u> OF THE UNC-W2-MEF CLONE OF <u>PLASMODIUM</u> <u>FALCIPARUM</u>	37
Table 21	39
Genealogy of adaptation trials in <u>Aotus</u> of the UNC-W2-MEF clone of <u>Plasmodium</u> <u>falciparum</u>	40
LITERATURE CITED	41
DISTRIBUTION LIST	42

#### EXPERIMENTAL PROCEDURES

Two monkey-adapted Plasmodium falciparum strains, Vietnam Smith (resistant to maximally tolerated doses of chloroquine, pyrimethamine, and quinine), and Uganda Palo Alto (sensitive to chloroquine and quinine, resistant to pyrimethamine) were used to induce experimental malaria infections in Aotus trivirgatus for the evaluation of the antimalarial efficacy of candidate drugs. Infected blood, with sodium citrate (2.5%) as the anticoagulant, from untreated Aotus was diluted appropriately with chilled saline (0.85%), such that each milliliter contained 5,000,000 parasites, and this amount was injected into the saphenous vein of experimental and control monkeys.

Blood films, prepared and examined daily beginning on the first post-inoculation day, were stained with Giemsa. Parasitemias were evaluated as follows: negative, if no parasites were detected on a thick blood film after examination for at least 5 minutes; <10 parasites per cmm, if positive only on the thick blood film; parasite enumeration was by the Earle-Perez method and reported as the number of parasites per cmm.

Blood films from untreated <u>Aotus</u>, serving as passage and/or control subjects, were prepared and examined daily during the primary patent period, and daily thereafter for at least three consecutive days after parasites could last be detected on thick blood films. When parasitemia had cleared, films were made and examined twice weekly until a total of 100 negative days had been recorded. If a recrudescence occurred, blood films were obtained again on a daily basis.

The schema depicted in Figure 1 represents the design of a typical drug evaluation study. Parasitemiaswere evaluated daily (or twice daily) during the treatment period and until blood films were negative for at least seven consecutive days. The frequency of smearing was then reduced to two times per week (Monday and Thursdays or Tuesdays and Fridays). If no recrudescences occurred during a 100 day examination period, the infection was considered to have been cured.

Drug doses were calculated as mg base per kg of body weight. Stock solution of water soluble compounds, at appropriate concentrations, were prepared with distilled water and stored at  $8^{\circ}$ C for the treatment period. If a compound was water insoluble, a suspension of the requisite amount of drug was prepared daily with 0.3% methylcellulose (in distilled water).


Oral administration of drugs was effected by gastric intubation with a 14 French catheter. The total amount of fluid administered, drug solution or suspension, and rinse was 14 ml. As will be indicated in subsequent sections, some drugs were administered other than by gastric intubation.

#### FIGURE 1

### SCHEMA FOR DRUG EVALUATION AGAINST

# PLASMODIUM FALCIPARUM

## INDUCED INFECTIONS IN AOTUS TRIVIRGATUS



ASSESSMENT OF THE ANTIMALARIAL ACTIVITY OF WR 250547AA (BN: BK 51630) AND WR 250548AA (BN: BK 51621) IN COMBINATION, AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

Both of these acridinal compounds are stereoisomers of floxacrine. The published (1) antimalarial activity of floxacrine against the multi-resistant Vietnam Smith strain of  $\underline{P}$ . falciparum indicated that the total-course  $CD_{50}$  and  $CD_{90}$  for previously untreated infections were 56.0 and 154.0 mg per kg, respectively. These doses were 6 x and 17 x greater than the 8.75 mg per kg course dose necessary for regular clearance of parasitemia.

Results of the evaluation of the two stereoisomers, singly, against infections of the Vietnam Smith strain were presented in a previous Annual Report (2). The data showed that WR 250547 at a dose of 1.0 mg base per kg (x 3) cured 1 of 2 primary infections and that doses of 4.0 or 16.0 mg base per kg (x 3) cured all primary infections. Primary Vietnam Smith infections were not cleared by WR 250548 at doses of 1.0 or 4.0 mg base per kg (x 3 days); a dose of 16.0 mg base per kg (x 3 days) cleared parasites, but did not cure the infection. Retreatment with higher doses was not uniformly curative.

Subsequently, evaluation of WR 250547 in combination with WR 250548 showed that a potentiating effect was obtained in vitro against P. falciparum and in vivo against P. berghei. (3). These observations provided the impetus to re-evaluate the combination of the two stereoisomers against Vietnam Smith infections in Aotus. The results of this study are presented in Tables 1,2 and 3. Equal doses, 0.5 mg base per kg ( x 3 days), of WR 250547 and WR 250548 cleared the parasitemia, but did not cure the infection. Re-treatment with the drugs each at a dose of 1.0 mg base per kg (x 3 days) cured the infection, and this dose of each drug cured a primary Vietnam Smith infection.

Administration (Aotus 11980) of WR 250547 at a dose of 0.5 mg base per kg (x 3 days) in combination with WR 250548 at a dose of 2.0 mg base per kg (x 3 days) only cleared the parasitemia. Retreatment with WR 250547 (1.0 mg base per kg x 3 days) plus WR 250548 (4.0 mg base per kg x 3 days) suppressed parasitemia. A second retreatment with WR 250547 at a dose of 2.0 mg base per kg (x 3 days) plus WR 250548 at a dose of 4.0 mg base per kg (x 3 days) cleared parasitemia, but did not cure the infection. Additional treatment was not possible due to insufficient drug.

A dose of 1.0 mg base per kg (x 3 days) of WR 250547 administered in combination with WR 250548 at a dose of 4.0 mg base per kg (x 3 days) cured the infection in Aotus 11856. The infection in Aotus 11977 was cured with WR 250547 (2.0 mg base per kg x 3 days) plus WR 250548 (0.5 mg base per kg x 3 days). WR 250 547 at a dose of 4.0 mg base per kg (x 3 days) plus WR 250548 at a dose of 1.0 mg base per kg (x 3 days) cured the infection in Aotus 11908.

#### CONCLUSION

The potentiating effect of WR 250547 for WR 250548 observed initially in the <u>P. berghei</u> rodent model has been confirmed in the <u>P. falcipaum - Aotus model</u>. The dosage combination evaluated of the two drugs show significantly greater activity of WR 250548 when administered with Wk 250547. The one failure in <u>Aotus 11980</u> to cure the infection may have resulted from the induction of parasite resistance to the drugs or the inability of the monkey to absorb/metabolize the drug (s).

DETAILED ACTIVITY OF THE COMBINATION OF WR 250547AA (BK 51630) AND WR 250548AA (BK 51621)
AGAINST INFECTIONS OF THE VIETNAM SAITH STRAIN OF PLASMODIUM FALCIPARUM

}					- 5 -						
		7	O <sub>i</sub>	0	0	0	0	0.8	0	0	0
		9	0.	0	0	0	0	0.2	0	0	0
	Treatment	5	0	0	0	<0.01*	0	0.1	0	0	0
	Day Post I	#	O	0	0	0	0	<0.01	0	<0.01	0
cmm x 10 <sup>3</sup>	Dê	го 	<001	0.3	<0.01	0	0	<0.01	(0.01	0.4	0
per		2	-	0.2	<0.01	<0.01	<0.01	<0.01	0.2	0.8	0
Parasitemia		+	2	9.0	<0.03	0.1	6.0	0.2	<b></b>	_	0
Ω4	Treatment	m	19	0.5	m	0.5	2	0.4	0.7	~	0.1
	of Treat	2	15	цs	4	т	ю	-	9	თ	ო
	Dav		18	т	11	м	10	<0.01	2	15	-
	Day	Pre-	0.9	_	11	0.8	٦	(0.01	2	2	2
	Daily	Mg/Kr	0.5a 0.5b	1.0a	1.0b 1.0a 1.0b	0.5a 2.0b	1.0a 4.0b	1.0a <0.01 4.0b	2.0a 0.5b	4.0a	1.0b
	Aotus	NO.	11803	11976	11803r	11980	11856	11980r	11977	11908	11980rr

a = WR 250547AA b = WR 250548AA \*= drug form

TABLE 2

SUMMARY OF THE ACTIVITY OF THE COMBINATION OF WR 250547AA (BK 51630) AND WR 250548AA (BK 51621) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF <u>PLASMODIUM FALCIPARUM</u>

Monkey	Daily Dose y 3	Response	of Parasitemia	nia to Rx	Davs from Initial Px	Davs from Final Rx	
No.		None	Suppressed	Cleared	to Parasite Clearance	To Recru- descence	Motes
11803	0.5a 0.5b			+	7	18	Re-Rx, higher dose
9/611	1.0a			+	7	n.a.	Cured
11803r	1.0b			+	7	n.a.	Cured
11980	0.5a 2.0b			+	თ	14	Re-Rx, higher dose
11856	1.0a 4.0b			+	9	n.a.	Cured
11980r	1.0a		+		n.a.	n.a.	Re-Rx, higher dose
11977	7.05 0.5b			+	7	n.a.	Cured
11908	4.0a 1.0b			+	œ	n.a.	Cured
11980rr	2.0a 4.0b			+	4	19	Drug Q.N.S. for Re-Rx

a = WR 250547AAb = WR 250548AA

MALARIA	DOSE	mg/kg	PRIMARY TR	EATMENTS	REPEAT TRE	EATMENTS	TOTAL TRE	ATMENTS
STRAIN	TOTAL	DAILY	CLEARED	CURED	CLEARED	CURED	CLEARED	CURED
Smith	1.5a 1.5b	0.5 0.5	1/1	0/1			1/1	0/1
	3.0a 3.0b	1.0 1.0	1/1	1/1	1/1	1/1	2/2	2/2
	1.5a 6.0b	0.5 2.0	1/1	0/1			1/1	0/1
	3.0a 12.0b	1.0 4.0	1/1	1/1	1/1	0/1	2/2	1/2
	6.0a 1.5a	2.0 0.5	1/1	1/1			1/1	1/1
	12.0a 3.0b	4.0 1.0	1/1	1/1			1/1	1/1
	6.0a 12.0b	2.0 4.0	1/1	0/1			1/1	0/1

a= WR 250547AA b= WR 250548AA

ASSESSMENT OF THE ANTIMALARIAL ACTIVITIES THREE 9-PHENANTHRENEMETHANOLS AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

The antimalarial activities in owl monkeys of diverse 9-phenanthrenemethanols have been reported (4). Two drugs in this class, WR 171669 (subsequently called halofantrine) and WR 122755 were highly active. WR 122455 was four times as active as chloroquine against chloroquine - sensitive P. falciparum strains and WR 171669 was equal to the activity of chloroquine.

Evaluation of these two agents in human volunteers (5) infected with the multi-drug resistant Vietnam Smith strain of P. falciparum showed that WR 122455 at 480 mg per day for 3 to 6 days cured 9 of 9 such infections. WR 171669 administered at 1.0 gm per day for 3 days cured 6 of 6 volunteers intected with the Smith strain. Large doses of both drugs evoked gastrointestinal symptoms - nausea, vomiting, abdominal pain and diarrhea.

Based upon additional data (3) it was believed that the biquinate salt of halofantine would enhance the bioavailability of halofantrine. Both compounds were assessed in parallel studies against infections of the Vietnam Smith strain and also included was a re-assessment of WR 122455.

## A. WR 171669AM (BN: BK 64002)

The activity of the chloride salt of halofantrine is detailed in Table 4, and summarized in Tables 5 and 6. The data indicate that doses of 2.92, 5.83, or 11.67 mg base per kg ( x 3 days) had either no effect or a suppressive effect upon primary Vietnam Smith parasitemias. Retreatment with a dose of 5.83 mg base per kg ( x 3 days) in two monkeys only suppressed parasitemia. In four Actus retreated with a dose of 11.67 mg base per kg (x 3 days), the parasitemia was suppressed in two monkeys, and cleared in two; the infection was cleared in one of the latter animals.

A dose of 23.3 mg base per kg (x 3 days) only suppressed parasitemia in two monkeys and cleared the parasites, but did not cure, in two Aotus. Parasitemias were cleared in 4 of 4 Aotus with a dose of 46.6 mg base per kg ( $\times$  3 days), but infections were not cured. One of two recrudescences was cured with a dose of 93.2 mg base per kg ( $\times$  3 days). No apparent toxic reactions occurred.

Four treatment failures were included in the WR 122455 assessment.

# B. WR 171669AP (BN: BL 08009)

The biquinate salt of halofantrine was evaluated at the same doses as WR 171669AM. Detailed results are presented in Table 7, and summarized in Tables 8 and 9. Primary parasitemias were either not affected or suppressed with doses of 2.92, 5.83 or 11.67 mg base per kg (x 3 days). Retreatment with a dose of 5.83 mg base per kg (x 3 days) suppressed parasitemia, and retreatment with a dose of 11.67 mg base per kg (x 3 days) suppressed parasitemia in one Aotus and cleared parasitemia in 3 of 3 monkeys. Infections in the latter three monkeys were not cured.

Parasitemias in 6 of 6 <u>Aotus</u> retreated with a dose 23.3 mg base per kg (x 3 days) were cleared, but infections were not cured. Retreatment with a dose of 46.6 mg base per kg (x 3 days) cured the infection in 1 of 3 <u>Aotus</u>, and cleared parasitemias only in 2 of 3 monkeys.

Recrudescences in five Aotus were treated with WR 122455.

### C. WR 122455AF (BN: AX26839)

Assessment of the hydrochloride salt of WR 122455 included primary Vietnam Smith parasitemias and recrudescences following multiple re-treatments with either WR 171669AM or WR 171669AP. The detailed activity is presented in Table 10 and summarized in Tables 11 and 12.

A dose of 2.92 mg base per kg (x 3 days) suppressed parasitemia in 2 of 2 Aotus. Two of 2 primary parasitemias were cleared at a dose of 5.83 mg base per kg (x 3 days), and the infection cured in one monkey. A dose of 11.67 mg base per kg (x 3 days) cured 2 of 2 primary infections.

Recrudescent parasitemias after re-treatments with either WR 171669AM or WR 171669AP, were cleared with WR 122455 at a dose of 2.92 mg base per kg (x 3 days); the infection in one <u>Aotus</u> was cured. Treatment with WR 122455 at a dose of 5.83 or 11.67 mg base per kg (x 3 days) respectively cured 7 of 7 and 4 of  $4_{\kappa}$  treatment failures with either WR 171669AM or WR 171669AP.

#### CONCLUSION

At the doses used, halofantrine (WR 171699AM) was essentially inactive against infections in <u>Aotus</u> of the multi-drug resistant Vietnam Smith strain of <u>P. falciparum</u>. In a total of 22 treatments, parasitemia was cleared in 9 cases with cure of only two infections. The biquinate salt (WR 171699AP) of halofantrine cleared 10 parasitemias in a total of 21 treatments, but only one infection was cured. The effective antimalarial activity of WR 122455 was evidenced by the parasite clearance in 17 of 19 treatments, and infection cure in 15 of 19 treatments. All treatment failures with either WR 171669AM or WR 171669AP were cured by WR 122455.

TABLE 4

DETAILED ACTIVITY OF WR 171669AM (BK 64002) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

1	ı	Н		13 -			
				Re-Rx higher dose 0	Higher dose 0 0 <0.01	0 0 \$0.01 \$0.01	0.7
	9	a a	e er dose er dose	0.01 Re-Rx, 0	Re-Rx, <0.01 <0.01	0 0 0 0	, 0 4
Treatment	5	higher dose higher dose	, higher dose , higher dose Re-Rx, higher Re-Rx, higher	higher dose higher dose <0.01 / 59 0	0.2 0 0 <0.01	0 0 0 0	0.7
Post	<b>3</b>	Re-Rx, Re-Rx,	Re-Rx, 159 R 85 R	Re-Rx, Re-Rx, <0.01 331 0 <0.01	0.8 <0.01 <0.00	0000	<0.01 1
n x 10 <sup>3</sup>	3	426 169	373 766 63 60	995 82 <0.01 164 0	26 <0.01 0 <0.01	0000	0.3
a per cmm	2	462 195	249 1064 106 10	461 212 0.4 142 <0.01	73 0.2 0 <0.01	0000	<0.01 0.4
Parasitemia	1	81 122	90 373 15 53	214 24 0.7 141 0.4	497 0.7 0.3	<0.01 0 0	0.2
	e e	149 107	211 382 186 86	391 51 72 792 0.3	427 2 <0.01 2	(0.0) (0.0) (0.0)	e 2
of Treatment	5	17	13 43 382 364	39 18 419 1136 7	995 71 1	<pre>&lt;0.01 0.2 &lt;0.01 &lt;0.01</pre>	115 3
Dav		18	13 368 409 38	27 20 218 595 58 1115	852 80 0.4 146	0.3 (0.01 (0.01	151
	Prov.	m 2	4 4 426 169	4 373 766 159 85	995 82 0.01 59	0.2 0.2 <0.01 <b>&lt;</b> 0.01	37
  Daily  Dose	Mg/Kg	2.92	5.83 833 83	11.67 11.67 11.67 11.67 11.67	23.3 23.3 23.3 >	46.6 46.6 46.6 46.6	93.2
Aotus	No.	11518 11873	11517 11702 11518r 11873r	11740 11904 11517r 11702r 11518rr 11873rr	11740r 11904r 11517rr 11702rr	11740rr 11904rr 11517rrr 11702rrr	11740rrr 1¶702rrrr

TABLE 5

SUMMARY OF THE ACTIVITY OF WR 171669AM (BK 64002) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

7	Daily	Response of	of Parasitemia	ia to Rx	Davs from Initial Px	Davs from Final Rx	
No.	Mg/Kg	None	Suppressed	Cleared	Clearance	descence	Notes
11518	2.92	+			n.a.	Л.а.	Re-Rx, higher dose
11873	2.92		+1		n.a.	n.a.	Re-Rx, higher dose
11517	5.83		+		n.a.	n.a.	
11702	5.83	+			n.a.	n.a.	
11518r	5.83		+1		n.a.	n.a.	
11873r	5.83		+		n.a.	n.a.	Re-Rx, higher dose
11740	11.67	+			n.a.	n.a.	Re-Rx, higher dose
1904	11.67		+		n.a.	n.a.	Re-Rx, higher dose
11517r	11.67		+		n.a.	n.a.	higher
11702r	11.67		+		n.a.	n.a.	Re-Rx, higher dose
11518rr	11.67			+	5	n.a.	Cured
11873rr	11.67			+	10	36	Rx, new drug
11740r	23.3		+		п.а.	n.a.	Re-Rx, higher dose
11904r	23.3			+	10	53	higher
11517rr	23.3			+	4	2]	higher
11702rr	23.3		+		n.a.	n.a.	Re-Rx, higher dose

TABLE 5 (CONT'D)

SUMMARY OF THE ACTIVITY OF WR 171669AM (BK 64002) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

	Daily	Response	Response of Parasitemia to Rx	nia to Rx	Davs from Initial Px	Days from Final Rx	
No.	Mg/Kg	None	Suppressed Cleared	Cleared	to rarasite Clearance	To Recru- descence	Notes
11740rr 11904rr 11517rrr 11702rrr	46.6 46.6 46.6 46.6			+ + + +	<b>ለ</b> 446	20 8 5 6	Re-Rx, higher dose Rx, new drug Rx, new drug Re-Rx, higher dose
11740 rrr 11702rrr	93.2 93.2		+	+	8 n.a.	n.a. n.a.	Cured Rx, new drug

TABLE 6

SUMMARY OF THE ANTIMALARIAL ACTIVITY OF WR 171669AM (BK 64002) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

MALARIA	DOSE	mg/kg	PRIMARY TR	REATMENTS	REPENT TR	EATMENTS	TOTAL TRE	ATHENTS
STRAIN	TOTAL	DAILY	CLEARED	CURED	CLEARED	CUKED	CLEARED	CURED
Smith	8.76	2.92	0/2	0/2			0/2	0/2
	17.49	5.83	0/2	0/2	0/2	0/2	0/4	0/4
	35.01	11.67	0/2	0/2	2/4	1/4	2/6	1/6
	69.9	23.3			2/4	0/4	2/4	0/4
	139.8	46.6			4/4	0/4	4/4	0/4
	279.6	93.2			1/2	1/2	1/2	1/2

DETAILED ACTIVITY OF WR 171669AP (BL 08009) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

1				- 17	-				
		6	·	Re-RX	< 0.01	000	900	000	000
		ع	dose	dose dose <0.01	dose dose 0	000	000	000	000
	Treatment	2	higher	igher igher .01	igher igher 0	(0.0) 000	000	000	000
	Post	t	Re-Rx,	Re-Rx, 1 Re-Rx, 1 C 0.01 C 0	Re-Rx, h Re-Rx, h <0.01	[0.0 V	<0.01 <0.01 0	000	000
# # # # # # # # # # # # # # # # # # #	×	3	173	320 45 <0.01 <0.01	102	000	<0.03 <0.03 0	000	<b>&lt;</b> 0.01 0
ت و د	Tal.	2	160 315	80 200 0.4 0.2	204	+00 0	0.3	0 0 <0.03	000
Parasitemia		1	87 151	42 71 2	64 3 0.6	100	0.8 0.07 0	<b>^</b> 0.0 <b>^</b>	000
	Treatment	æ	293 204	102 83 22 17	42 5 1	(0.0)	43 0.5 <0.01	0.4	<b>&lt;</b> 0.01 <0.01 <0.01
	of	2	30	15 28 337 87	20 15 58 84	<0.01 <0.01	105 20 <b>&lt;</b> 0.01	0.0 0.9	<b>&lt;</b> 0.01 <b>&lt;</b> 0.01 0.4
	Dav	<b>←</b> 1	18 49	8 18 240 284	19 16 256 209	<0.01 0.4	140 48 <0.01	) E –	<0.01 <0.01 1
_	Day	R X	23	. 3 173 461	4 2 320 45	0.01	102 4 4 4 4 60.01	0.3	(0.01 (0.01 0.6
	Dailv   Dose   Mg/Kg	, 5, .	2.92	5.83 5.83 5.83	79.	11.67 <	23.3		46.6 < 46.6 < 46.6 < 46.6
	Aotus No.		11780	11781 11899 11780r 11811r	11779 11898 11781r 11899r	11780rr 11811rr	11779r 11898r 11781rr 11899rr	11780rr 11811rr	11779rr 11898rr 11781rrr

SUMMARY OF THE ACTIVITY OF WR 171669AP (BL 08009) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM TABLE 8

Monkey	Daily Dose x 3	Response	e of Parasitemia	to Rx	Davs from Initial Px	Davs from Final Rx	
No.	<b>F</b> 0	None	Suppressed	Cleared	to Parasite Clearance	To Recru- descence	Motes
11780	2.92	+	+1		n.a.	n.a.	
,	l (				a.	n.a.	Re-Rx, higher dose
11899	5.83 83.33		+  -		n.a.	n.a.	Re-Rx, higher dose
11780r	, r , c		+ 1-		n.a.	п.а.	higher
11811	, r , c , c		<b>⊦</b> -		n.a.	n.a.	higher
-	5		+		n.a.	n.a.	higher
11779	11.67		+		2	, 5	
11898	11.67		+			. a .	
11781	11 67		<b>-</b> -		n.a.	n.a.	
118995	11.67		+		n.a.	n.a.	
11780rr	11.67			+ -	σ,	_3	Re-Rx, higher dose
11811rr	11.67			+ -	4.	20	
2	ò			+	4	25	Re-Rx, higher dose
11779r	23.3			+	c		
11898r	23.3			- 4	<b>o</b> (	, ,	higher
11781rr	23.3			٠ -	χο •	= ;	higher
1189955	22.3			+ .	7 (	12	Re-Rx, higher dose
11780rr	22.5			+ ·	2	27	Rx, new drug
11811	22.3			+ ·	.c. (	<del></del>	
	0.0			+	9	20	
11779rr	46.6			4	٢	Ľ	
11898rr	46.6			÷ +	~ <	72	Rx, new drug
11781rrr	46.6			- 4	<b>;</b>	<b>57</b>	Kx, new drug
				٠	4	n.a.	Cured

TABLE 9

SUMMARY OF THE ANTIMALARIAL ACTIVITY OF WR 171669AP (BL 08009) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

MALAR IA	DOSE	mg/kg	PRIMARY TR	EATMENTS	REPEAT TR	EATMENTS	TOTAL TRE	ATMENTS
STRAIN	TOTAL	DAILY	CLEARED	CURED	CLEARED	CURED	CLEARED	CURED
Smith	8.76 17.49 35.01 69.9 139.8	2.92 5.83 11.67 23.3 46.6	0/2 0/2 0/2	0/2 0/2 0/2	0/2 1/4 6/6 3/3	0/2 0/4 0/6 1/3	0/2 0/4 1/6 6/6 3/3	0/2 0/4 0/6 0/6 1/3

DETAILED ACTIVITY OF WR 122455AF (AX 26839) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM TABLE 10

			<b>T.</b>		- 2	0	-												
	7	0.3	0.0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	9	-	0.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
reatment	ហ	0.4	0.2 0	0	0	0	0	0	<0.01	0	0	0	0	0	0	0	0	0	0
Post	ੜ	2	-0	0	<0.01	0	0	0	<0.01	0	0	0	0	0	0	0	0	0	0
Da	3	7	m 0	0	0.2	0.3	0	0	0.3	0	0	0	0	<0.01	<0.01	0	0	0	0
	2	25	00	0	0.7	9.0	<0.01	0	0.1	0	0	0	0	0.1	0.1	0	0	0	0
	<b>←</b> 4	42	130 <b>&lt;</b> 0.01	0	6	22	<0.03	0	0.5	0	< 0.01	<0.01	0	_	2	<0.01	0	<0.01	0
tment	æ	80	231 <b>&lt;</b> 0.01	0	16	101	0.2	0	_	0.4	0.2	8.0	<0.01	10	15	0.2	<0.01	0.4	<0.01
of	2	20	40 0.2	0	20	51	0.2	<0.01	14	_	2	_	0.7	64	19	0.4	<0.01	0.5	0.5
ļ 	1	11	58 0.4	0	10	69	_	<0.01	82	13	2	_	_	55	42	0.5	<0.01	Ξ	0.3
Day	Pre-	4	0.1	0.01	က	9		· 0				0.3	2	4	m	0.1		2	0.1
Daily Dose	1147 KF	2.92			5.83	5.83	5.83	_	5.83	5.83	5.83	5.83	5.83	11.67	11.67	11.67	11.67	11.67	11.67
		11492	11876 11517rrrr	11780rrr	11544	11875	11492r	11876r	11779rrr	11898rrr	11904rrr	11811rrrr	11730rrrrr	11773	11775	11544r	11873rrr	11899rrr	11702rrrr
	Dose Day Day of Treatment Day Po	Dose Day Day of Treatment Day Post Treatment Mg/Kr Pre- 1 2 3 $\mu$ 5 6	Day Post Treatment         Day Post Treatment           Mg/Kr         Pre- FX         1         2         3         4         5         6         7           2.92         4         11         20         80         42         25         7         2         0.4         1         0.3	Dose   Day of Treatment   Day Post Treatment   Day Post Treatment   Day of Treatment   Day of Treatment   Day of Treatment   Day Post Treatment   Day Ost Treatment   Day Post	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Dose Dose Dose Dose Dose Dose Dose Dose	Day of Treatment   Day Post Treatment   Day Post Treatment   Day Post Treatment     Day of Treatment   Day Post Treatment     Day of Treatment   Day Post Treatment     Day Post Treatment   Day Pos	Day Post Treatment   Day Pos	Dose Day Post Treatment         Day of Treatment         Day Fost Treatment           1 2 3         1 2 3         1 2 3         4 5 6 7           2.92 3 58 40 231 130 10 3         1 0.2 0.4 11 0.2 0.3 130 10 3 1 0.2 0.5 0.1 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Dose   Day Of Treatment   Day Post Treatment   Da	Dose   Day   Pre-   1	Dose   Day Of Treatment   Day Post Treatment   Da	Dose   Day   Day of Treatment   Day Post Treatmen	Cose   Day Of Treatment   Day Post Treatment   Da	Call   Day of Treatment   Day Post Treatment   Da	Logal IV Project         Day Post Treatment         Day Post Treatment         Day Post Treatment           2.92         3         4         5         6         7           2.92         3         4         5         6         7           2.92         3         4         5         6         7           2.92         3         4         2         6         7           2.92         3         4         0.2         6.01         0.01         0           7.92         0.1         0.4         0.2         6.01         0         0         0           7.83         2         0.1         0.4         0.2         6.01         0         0         0           7.83         0.0         0.1         0.0         0         0         0         0         0         0           7.83         0.0         82         14         1         0.2         6.01         0	Cose   Day of Treatment   Day Post Treatment   Day Post Treatment   Day Fost Treatment   Day of Treatment   Day of Treatment   Day Fost Treatment   Day Fo	Call   Call	Cost   Day   Day of Treatment   Day Post Treatmen

**TABLE 11** 

SUMMARY OF THE ACTIVITY OF WR 122455AF (AX 26839) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

Motes	Re-Rx, higher dose Re-Rx, higher dose Cured Re-Rx, higher dose	Re-Rx, higher dose Cured Cured Cured Cured Cured Cured	Cured Cured Cured Cured Cured
Davs from Final Rx To Recru- descence	n.a. n.a. n.a. 46	40 	
Davs from Initial Px to Parasite Clearance	n.a. 5	&/@40472724	~ <i>L</i> 2 4 5 4
nia to Rx Cleaned	+ +	+ + + + + + + +	+ + + + + +
of Parasitemia	<b>+</b> +		
Response			
Daily Dose x 3	2.92 2.92 2.92 2.92 2.92		11.67 11.67 11.67 11.67 11.67
Monkey No.	2 6 7rrr Orrr	11544 11875 11492r 11876r 11779rrr 11898rrr 11904rrr 11811rrrr	11773 11775 11544r 11873rrr 11899rrr 11702rrrrr

TABLE 12

SUMMARY OF THE ANTIMALARIAL ACTIVITY OF WR 122455AF (AX 26839) AGAINST INFECTIONS OF THE VIETNAM SMITH STRAIN OF PLASMODIUM FALCIPARUM

MALARIA	DOSE	mg/kg	PRIMARY TR	EATMENTS	REPEAT TRE	EATMENTS	TOTAL TRE	ATMENTS	
STRAIN	TOTAL	DAILY	CLEARED	CURED	CLEARED	CURED	CLEARED	CURED	
Smith	8.76 17.49 35.01	2.92 5.83 11.67	0/2 2/2 2/2	0/2 1/2 2/2	2/2 7/7 4/4	1/2 7/7 4/4	2/4 9/9 6/6	1/4 8/9 6/6	

ASSESSMENT OF THE ANTIMALARIAL ACTIVITIES OF 2-FLUORO-L-HISTIDINE AND 2-IODO-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM

A pilot evaluation (6) of 2-fluoro-1-histidine (WR 251853AA; BN: BK 70877) indicated that a total daily dose of 25.0 mg base per kg (x 7 days) suppressed parasitemia of the Uganda Palo Alto strain in 1 of 2 treated Aotus. Parasitemias in 2 of 2-Aotus were suppressed by a total daily dose of 50.0 mg base per kg (x 6 days); however, both animals died, on the sixth day of treatment, of probable drug toxicity. Since in vitro studies at the Malaria Section Laboratory, National Institutes of Health, Bethesda, Md., have shown that 2-fluoro-1-histidine will inhibit both parasite growth and knob formation of parasitized erythrocytes, additional in-vivo studies were considered to be of value.

Accordingly, Dr. Lindsey Panton (from NIH) was at Gorgas Memorial Laboratory for one month in a cooperative effort to re-evaluate 2-fluoro-1-histidine and a less toxic histidine, 2-iodo-histidine. Drugs were provided by Dr. Panton. Also, Dr. Carter Atkinson, Case Western Reserve University (Dr. Aikawas' laboratory), Cleveland, Ohio obtained tissue samples from treated and control monkeys for election microscopy determination of parasite sequestration.

#### A. 2-fluoro-1-histidine

This histidine was re-evaluated in a total of four Aotus infected with the Uganda Palo Alto strain (Tables 13 and 14). Two monkeys each were treated (intravenously) with a single 50.0 mg base per kg dose and each of two Aotus were treated (intravenously) with a single 100.0 mg base per kg dose. The 50.0 mg base per kg dose had no effect upon parasitemia in either monkey and one monkey was sacrificed for tissues on day 4, post treatment.

Parasitemia in Aotus 11379 was suppressed by a 100.0 mg base per kg dose. The parasite clearance (23 days post treatment) was not considered to be the result of drug action, but represented the length of a normal patent period (24.1 + 4.8 days) during the primary attack of infections with the Uganda Palo Alto strain of P. falciparum (7). The parasitemia in Aotus 11997 was not suppressed by a single 100.0 mg base per kg dose; the monkey was sacrificed on day 7 post treatment for tissues.

### B. 2-iodo-histidine

This analogue of the amino acid, histidine, was first evaluated by a single dose administered intravenously to monkeys infected with the Uganda Palo Alto strain. The data presented in Tables 15 and 17 show that a dose of 200.0 or 400.0 mg per kg had no effect upon parasitemia in each of four <u>Aotus</u>.

Monkeys were then retreated each with a 100.0 mg per kg dose (oral) as follows: day 1 - one dose in the afternoon, day 2 - one dose in the morning and one in the afternoon. Results shown in Tables 16 and 18 that this course of treatment had no effect upon parasitemia and the animals succumbed to malaria infection.

## CONCLUSION

The significant in vitro activity of these histidines was not evident in the in vivo evaluation, as measured by the lack of effect upon parasitemia. The examination of tissues by election microscopy is in progress.

DETAILED ACTIVITY OF 2-FLUORO-L-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PLASMODIUM FALCIPARUM

						Par	Parasitemia per cmm x 10 <sup>3</sup>	per cmm >	4 103			
Aotus No.	Dose*	Day Pre-	RX				Day	Day Post Treatment	3atment			
		N X	7-1	Ŧ	2	3	11	5	G	7	α	c
11353	50.0 AM	10	100	310	408 80	311	634 506	521	338	580	284	265
11613	50.0 AM PM	9	231 423	109 487	992 350	701 1232	1460 Sacrificed	pa		-	075	382
11379	100.0 AM .	. 5	31	4 ડ	7	30	47 36	142	48	267 169	249	110
1997	100.0 AM	ιΩ	141	77 140	409 321	149 214	1172	595	1331	1510 Sacrificed		- 27 -

\*Intravenous administration

TABLE 14

SUMMARY OF THE ACTIVITY OF 2-FLUORO-L-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM

	2	Notes		Carrie Long Daniel	saci il iceu pay 4 post-Rx	Sacrificed Day 7 post-Rx
Davs from Final Rx	To Recru-			n.a.		n.a.
Davs from Initial Px	to Parasite Clearance		17	n.a.	23	n.a.
Response of Parasitemia to Rx	Suppressed Cleared			4	•	
Respons	None	4	- →	-	+	
	Mg/Kg	50.0	50.0	100.0	100.0	
Monkey	No.	11353	11613	11379	11997	

\* Intravenous administration

DETAILED ACTIVITY OF 2-IODO-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM TABLE 15

Parasitemia per cmm x 10³	Day Post Treatment	6 8 2 9 5 1	Re-Rx, different dose and route			
		2	320 400	284 52	7.46 290	639 568
		71	80 142	25 175	31 609	71
	RX XX		106 118	40 35	122	134
	Day	7. K.	e e	2	. 4	7
	Dose Mg/Kg		200.0 AM	200.0 AM	400.0 AM	400.0 AM PM
	Aotus No.		11486	11581	11585	12253

\* Intravenous administration

DETAILED ACTIVITY OF RETREATMENT WITH 2-IODO-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM

		a			- 30	-
		7				
	reatment	9		alaria	alaria	
	Day Post Treatment	5	817 Died - malaria	639 Died - malaria	543 Died - malaria	
m x 103		4	317 Died -	142	462	
a per cm		8	781	533	462	Died - malaria
Parasitemia per cmm x 103	asitemia	(7	846	9/29	604	Died ~
Pa			568 768	249 568	750 320	521 604
	Dav of Rx	2	187 639	639 710	923 959	817
		-	400	52	290	568
Pailv —	Dose * Day	RX	100.0 AM PM	100.0 AM FM	100.0 AM PM	100.0 AM PM
	Aotus No.		11486r	11581	11585r	12253r

TABLE 17

SUMMARY OF THE ACTIVITY OF 2-IODO-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM

			io res	Re-Rx, different dose and route	ביים ביים מוח ביים מוח ביים מיים ביים ביים ביים ביים ביים ביים	Re-Rx, different dose and route Re-Rx, different dose and route
	Davs from Final Rx	To Recru- descence		ח.מ.		n.a. n.a.
	Davs from Initial Px	to Parasite Clearance		n.a. n.a.	: :	 ה.מ.
	ia to Rx	Cleared				
of Parasitem:	Response of Parasitemia	Suppressed				
	Response	None		+ +	+	+
	Daily Dose x1	Daily Dose x1 Mg/Kg		200.0	400.0	400.0
	Monkev	No.	11486	11581	11585	12253

\* Intravenous

TABLE 18

SUMMARY OF THE ACTIVITY OF 2-IODO-HISTIDINE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM

	Notes	Died Day 5, post Rx, malaria Died Day 5, post Rx, malaria Died Day 5, post Rx, malaria Died Day 2, post Rx, malaria
Davs from Final Rx	To Recru- descence	n.a. n.a. n.a.
Davs from Initial Px	to rarasite Clearance	n.a. n.a. n.a.
Response of Parasitemia to Rx	None Suppressed Cleared	+ + + +
Daily * Re	Mg/Kg	11486r 100.0 11581r 100.0 11585r 100.0 12253r 100.0

\* Administered orally - Day 1 - P.M., Day 2 - A.M.& P.M.

# PILOT EVALUATION OF SODIUM ARTESUNATE AGAINST INFECTION OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM

Q-inghaosu (QHS), artemisinin) was isolated by Chinese chemists in 1971 from the herb Artemisia annua (8). The herb had been used for more than 10 centuries in China as treatment for fevers and malaria, QHS has been used successfully against P. falciparum infections in man either chloroquine-sensitive or chloroquine - resistant strains. A derivative of QHS, is the water soluble sodium artesunate, more active than QHS against chloroquine - resistant and chloroquine - sensitive strains of P. berghei. Sodium artesunate has proven to be effective in human cases of cerebral malaria. There have been no systematic studies evaluating sodium artesunate in the P. falciparum - Aotus model. The present evaluation was limited to but a single Aotus because of the restricted availability of the drug.

Doses of sodium artesunate, each at 30.0 mg per kg, were administered intravenously on days 1 and 2 of treatment, to <u>Aotus</u> 11488 (Tables 19 and 20). The parasitemia was suppressed during days 2 through 6 post treatment, but then increased to pre-treatment level. The parasitemia cleared on day 18 after the first day of treatment.

It is to be noted that the drug was not completely water soluble.

### CONCLUSION

Based upon one  $\underline{\text{Aotus}}$  infected with the chloroquine-sensitive Uganda Palo Alto strain, a 30.0~mg per kg dose (x 2 days) suppressed the parasitemia. Further studies are pending upon the availability of additional drug.

DETAILED ACTIVITY OF NA ARTESUNATE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF PLASMODIUM FALCIPARUM TABLE 19

	80	150 378	
		7	231
	Day Post Treatment	9	7 99
	ay Post	5	36
$mm \times 10^3$	Ď	4	4 1
a per c	Parasitemia per cmm x 10 <sup>3</sup>	3	10
arasitemi		2	28
Δ,		1	67
	Day of Rx	2	57 109
		1	160 247
Daily	Dose * Day	Rx	30.0 A.M. 251 P.M.
	Aotus No.		11488

\* Intravenous

TABLE 20

SUMMARY OF THE ACTIVITY OF NA ARTESUNATE AGAINST INFECTIONS OF THE UGANDA PALO ALTO STRAIN OF <u>PLASMODIUM FALCIPARUM</u>

	Notes	Cured
Days from Final Rx	To Recru- descence	n.a.
Days from Initial Px	to Parasite Clearance	18
Response of Parasitemia to Rx	None Suppressed Cleared	+1
Daily *		30.0
Monkey	No.	11488

\* Intravenous

## ADAPTATION TRIALS IN AOTUS OF THE UNC-W2-MEF CLONE OF PLASMODIUM FALCIPARUM

Although not a primary goal, it was stipulated at the inception of this contract 10 years ago that new strains of  $\underline{P}$ .  $\underline{falciparum}$  or  $\underline{P}$ .  $\underline{vivax}$  may have to be adapted to  $\underline{Aotus}$  to accomplish a specific purpose. The  $\underline{CDC}$  Indochina III strain of  $\underline{P}$ .  $\underline{falciparum}$  is resistant to fansidar and chloroquine. The UNC-W2 clone of this strain was made resistant to mefloquine during two years of continuous mefloquine pressure  $\underline{in}$   $\underline{vitro}$  (3). The UNC-W2-MEF clone is 4x more resistant to mefloquine than the parent clone.

A culture of the UNC-W2-MEF clone was provided by MAJ W.K. Milhous, Walter Reed Army Institute of Research, for adaptation trials to <u>Aotus</u>. The genealogy shows, to date, the adaptation trials in <u>Aotus</u> of diverse origin. Details are presented in Table 21. Two monkeys, 8348 and 11614, were each inoculated intravenously with approximately  $100 \times 10^6$  parasites from the in vitro culture.

Blood films obtained from Colombian <u>Aotus</u> 8348 (splenectomized) were negative for 14 consecutive days and the monkey was reinoculated with a frozen sample. A patent infection was established (Table 21) and parasites subinoculated to other recipients.

A patent parasitemia was not established during a 44 day examination period in Panamanian Aotus 11614 (splenectomized) following inoculation of parasites obtained from culture. Infected blood from 8348 was inoculated into 11614, but only a low-grade parasitemia (parasites detectable in thick blood films) ensued for 31 days. A second subinoculation of infected blood from 8348 did produce a countable parasitemia - maximum of 540 per mm<sup>3</sup>.

Parasite subinoculation from 8348 to Panamanian <u>Aotus</u> 11742 (splenectomized) produced patent period of 12 days, with a maximum parasitemia of 450 per cmm.

A hybrid <u>Aotus</u> (Colombian x Panamanian), not surgically altered, was inoculated with parasites from 8348. To date, a patent infection has not been established.

#### CONCLUSION

To date, the highest parasitemias obtained during this monkey adaptation procedure of the UNC-W2-MEF clone has been in a splenectomized Actus of Colombian origin. These parasitemias, however, are considerably lower than usually seen for well-adapted P. falciparum strains in Actus. Moreover, high parasitemias have not yet occurred in Panamanian Actus. Adaptation trials of this clone will continue.

TABLE 21 DETAILS OF ADAPTATION TRIALS IN AOTUS OF THE UNC-W2-MEF CLONE OF PLASMODIUM FALCIPARUM


Monk No.	No. Parasites Inoc. x 10 <sup>6</sup>	Pre-Patent PDDays	Maximum Parasitemia Per mm <sup>3</sup>	Patent Day	Patent PD-Days	Notes
8348(S,C)	100					Neg.14 Days-Reinoc with frozen sample
8348r	13	19	28,000 60,000 20,000	30 60 90	113	Subinoc 11614-Days 12 & 58 Subinoc 11742-Day 90 Subinoc 83005-Day 97
11614(S,P) 11614r 11614rr	100 9 44	1	 <10 540	  10	31 38	Neg. 44 Days
11742(S,P)	60	1	450	5	12	
83005(H)	2					Neg. 19 Days

S = Splenectomized C= Colombian Aotus P= Panamanian Aotus

r= Re-inoculated

Hybrid (Panamanian M, Colombian F) Aotus H=

## GENEALOGY OF ADAPTATION TRIALS IN ACTUS OF THE UNC-W2-MEF CLONE OF PLASMODIUM FALCIPARUM




(s)= Splenectomized
 \* = Aotus of Colombian origin
 \*\* = Hybrid (Panamanian M, Colombian F)
 \*\*\* = Aotus of Panamanian origin

#### LITERATURE CITED

- 1. Schmidt, L. H. 1979. Antimalarial properties of floxacrine, a dihydroacridinedione derivative. Antimicrob. Agents Chemother. 16: 475 485.
- 2. Rossan, R. N. 1983. Annual Report: Drug Evaluation in the <u>Plasmodium falciparum Aotus model</u>. 68 pp.
- 3. Milhous, W. K. Personal communication.
- 4. Schmidt, L. H., Crosby, R., Rasco, J. and Vaughan, D. 1978. Antimalarial activities of various 9-phenanthrenemethanols with special attention to WR-122,455 and WR-171, 669. <u>Antimicrob</u>. <u>Agents Chemother</u>. 14:292-314.
- 5. Rinehart, J., Arnold, J. and Canfield, C. 1976. Evaluation of two phenanthrenemethanols for antimalarial activity in man: WR 122455 and WR 171669. Am. J. Trop. Med. Hyg. 25: 769 774.
- 6. Rossan, R. N. 1985. Annual Report: Drug Evaluation in the <u>Plasmodium</u> falciparum Aotus Model. 43 pp.
- 7. Rossan, R. N., Harper, J. S. III, Davidson, D. E. Jr., Escajadillo, A., and Christensen, H. A. 1985. Comparison of <u>Plasmodium falciparum infections</u> in Panamanian and Colombian owl monkeys. <u>Am. J. Trop. Med. Hyg.</u> 34:1037-1047.
- 8. Klayman, D. 1985. Qinghaosu (artemisinin): An antimalarial drug from China. Science 228: 1049 1055.

## DISTRIBUTION LIST

12	copies	Director Walter Reed Army Institute of Research Walter Reed Army Medical Center ATTN: SGRD-UWZ-C Washington, DC 20307-5100
1	сору	Commander US Army Medical Research and Development Command ATTN: SGRD-RMS Fort Detrick, Frederick, Maryland 21701-5012
2	copies	Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC Cameron Station Alexandria, VA 22304-6145
1	сору	Dean School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20814-4799
1	сору	Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234-6100



ō ∗